IN-CYTES A HIGH-DENSITY MICROELECTRODE ARRAY PLATFORM FOR LARGE-SCALE INTRACELLULAR FUNCTIONAL ASSAYS

Projektinformationen

In-Cytes

ID Finanzhilfevereinbarung: 861712

DOI

10.3030/861712

Projekt abgeschlossen

EK-Unterschriftsdatum 9 August 2019

Startdatum 15 Oktober 2019

Enddatum 14 Januar 2021

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 135 500,00

EU-Beitrag

€ 135 500,00

Koordiniert durch

MAXWELL BIOSYSTEMS AG
Switzerland

Periodic Reporting for period 1 - In-Cytes (IN-CYTES A HIGH-DENSITY MICROELECTRODE ARRAY PLATFORM FOR LARGE-SCALE INTRACELLULAR FUNCTIONAL ASSAYS)

Berichtszeitraum: 2019-10-15 bis 2021-01-14

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

More than one billion people worldwide suffer from diseases of the central nervous system. Treating brain diseases costs annually € 1.4T in EU and US .
Despite efforts and increasing budgets dedicated by multinational pharmaceutical companies for developing new drugs to cure diseases of the nervous system, brain drugs are 45% less likely to succeed and progress than non-brain drugs.
There is a widening gap between the increasing demand for brain therapeutics and the decreasing success rate of new drug.

Neurons connect and communicate by electrical signals.
Neural connectivity is altered through brain diseases (e.g. Alzheimer’s disease, Schizophrenia, Autism, etc.).
In order to accurately measure neural connectivity, it is necessary to access neurons’ intracellular electrical signals.

The overall objectives of In-Cytes project include the development of a prototype in vitro electrophysiology platform providing a connectivity bioassay.
In-Cytes assay aims to reliably recording intracellular electrical signals from thousands of neurons, in order to assess drug effects on neuronal connectivity in human brain disease models, in vitro.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

"One of the main goal of the In-Cytes project was to train the Innovation Associate, in order to enable her to transition from an academic environment focusing on basic research to a business environment.
The Innovation associate was trained in an industrial R&D environment, including project management aspects and product applications (from cell cultures on MEA sensors to data analysis).
The innovation associate was also involved in customer support and satisfaction.
The innovation associate partitcaped to marketing events and successfully collaborated with industrial biotechnology partners, which lead to creation of application protocols.
The Innovation became a key employee at the hosting company for internal product development and to interface customers, therefore she was hired by a permanent position as ""Application Scientist"".
Importantly, the Innovation associated developed prototype assay enabling live identification of single-neurons and targeted electrical stimulation, enabling access to intracellular signals."

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

In-Cytes project enabled MaxWell Biosystem to explore the technical parameters required for single-neuron electrical stimulation, in order to develop the first high-throughput drug screening platform for recording intracellular electrical signals in neural networks. In-Cytes assay aims to be used in combination with human induced pluripotent stem cell technology, enabling drug screenings in human neurons modeling brain disease and reducing the use of animal models in preclinical drug discovery. In-Cytes assay will provide novel high-content electrophysiological parameters, which in turn will shorten the time to identify efficacious and safe drug for brain diseases.

In-Cytes Concept